Our results showed that both cell lines are sensitive to palbociclib (Supplemental Figure 7, E and F), reinforcing the fact that CDK inhibition is effective in treating cancers with the canonical Rb-E2F1 pathway. This evidence concerns the gene E2F1 and cancer.